Non-cytotoxic drugs as potential treatments for gliomas

Current Opinion in Neurology

Volumn 17, Issue 6, 2004, Pages 663-673

  Drappatz, Jan ^a   Wen, Patrick Y ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Intratumoral therapy; Malignant gliomas; Targeted molecular therapy

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AP 12009; AP 23573; CARMUSTINE; CILENGITIDE; DEPSIPEPTIDE; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LAPATINIB; LENALIDOMIDE; LOMUSTINE; LONAFARNIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RETINOID DERIVATIVE; SEMAXANIB; SI 27; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB; VORINOSTAT;

ANAPLASTIC CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; MAXIMUM PERMISSIBLE DOSE; PAPULAR SKIN DISEASE; RASH; REVIEW; THROMBOEMBOLISM; TOXICITY;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GLIOMA; GROWTH INHIBITORS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS;

EID: 10044265497     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200412000-00005     Document Type: Review

References (99)

1. Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 2003; 15:197-203.
2. Wen PY, Kesari S. Malignant gliomas. Curr Neurol Neurosci Rep 2004; 4:218-227.
3. Konopka G, Bonni A. Signaling pathways regulating gliomagenesis. Curr Mol Med 2003; 3:73-84. A recent review of signaling pathways in gliomas.
4. Mrugala M, Kesari S, Ramakrishna N, Wen PY. Therapy for recurrent malignant gliomas in adults. Expert Rev Anticancer Ther 2004; in press.
5. Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004; 7:618-635.
6. Nathoo N, Goldlust S, Vogelbaum MA. Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery 2004; 54:1480-1488.
7. Kleihues P, Cavenee WK. Tumours of the central nervous system: World Health Organization Classification of Tumors. In: Pathology and genetics. Lyon: IARC Press; 2000.
8. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15:1311-1333.
9. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radial Oncol Biol Phys 2004; 58:927-931. A recent review of the role of EGFR in radiation resistance in gliomas and potential therapeutic strategies.
10. Halatsch M-E, Gehrke EE, Vougioukas VI, et al. Inverse correlation of epidermal growth factor receptor (EGFR) mRNA induction and suppression of anchorage-independent growth by OSI-774, an EGFR tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J Neurosurg 2004; 100:523-533.
11. Raizer JJ, Abrey L, Wen P, et al. A phase II trial of OSI-774 (Tarceva) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. In: Proceedings of the American Society of Clinical Oncology. New Orleans, 4-8 June 2004 [Abstract 1502].
12. Prados M, Chang S, Burton E, et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. In: Proceedings of the American Society of Clinical Oncology. Chicago, IL, 31 May-3 June 2003 [Abstract 394].
13. Vogelbaum MA, Peereboom D, Stevens G, et al. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single-agent therapy of recurrent glioblastoma multiforme: interim results. In: Proceedings of the American Society of Clinical Oncology. New Orleans, 4-8 June 2004 [Abstract 1558].
14. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22:133-142.
15. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17:2572-2578.
16. Yung WYK, Prados MD, Yaya TR, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytomas or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999; 17:2762-2777.
17. Lieberman F, Cloughesy T, Deangelis LM, et al. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. In: Proceedings of the American Society of Clinical Oncology. New Orleans, 4-8 June 2004 [Abstract 1510].
18. Uhm JH, Ballman KV, Giannini JC, et al. Phase II study of ZD1839/Iressa® in patients with newly diagnosed grade 4 astrocytoma. In: Proceedings of the American Society of Clinical Oncology. New Orleans, 4-8 June 2004 [Abstract 1505].
19. Chakravarti A, Chakladar A, Delaney MA, et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002; 62:4307-4315.
20. Krishnan S, Rao RD, James CD, Sarkaria JN. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. Front Biosci 2003; 8:e1-e13.
21. Chakravarti A, Seiferheld W, Robbins I, et al. Phase I results from RTOG BR-0211, a phase I/II study of an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD 1839 (Iressa), with radiation therapy in glioblastoma multiforme (GBM). Int J Radiat Oncol Biol Phys 2003; 57 (2 Suppl.):S329.
22. Manley PW, Cowan-Jacob SW, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002; 38 (Suppl. 5):S19-S27.
23. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002; 38 (Suppl. 5) S28-S36.
24. Radford IR, Imatinib. Novartis. Curr Opin Invest Drugs 2002; 3:492-499.
25. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000; 60:5143-5150.
26. Wen PY, Yung WKA, Lamborn K, et al. Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99-08). Society for Neuro-Oncology, 9th Annual Meeting. Toronto, Canada, 18-21 November 2004.
27. Raymond E, Brandes A, Van Oosterom A, et al. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC: NDDG/ BTG Intergroup Study. In: Proceedings of the American Society of Clinical Oncology. New Orleans, 4-8 June 2004 [Abstract 1501].
28. Bredel M, Pollack IF. The p21-Ras-signal transduction pathway and growth regulation in human high-grade gliomas. Brain Res Brain Res Rev 1999; 29:232-249.
29. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 2003; 3:595-614. A detailed review of targeted molecular therapy for growth factor receptors and the Ras/MAP kinase pathway.
30. Cloughesy TF, Kuhn J, Wen P, et al. Two phase Il trials of R115777 (Zarnestra®) in patients with recurrent glioblastoma multiforme: a comparison of patients on enzyme-inducing anti-epileptic drugs (EIAED) and not on EIAED at maximum tolerated dose respectively, a North American Brain Tumor Consortium (NATC) Report. Neuro-Oncology 2003; 5:349 [Abstract TA-10].
31. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
32. Newton HB. Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/ PTCH, and angiogenesis. Expert Rev Anticancer Ther 2004; 4:105-128. A detailed review of targeted molecular therapy for PI3K pathway and anti-angiogenesis.
33. Chang SM, Kuhn J, Wen P, et al. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 2004; 22:427-435.
34. Chang S, Kuhn J, Wen P, et al. Phase II/pharmacokinetic study of CCI-779 in recurrent glioblastoma multiforme. Society For Neuro-Oncology, 8th Annual Meeting 2003. Neuro-Oncology 2003; 5:349 [Abstract TA-09].
35. Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Cancer Rev 2001; 1:194-202.
36. Kim MS, Blake M, Baek JH, et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63:7291-7300.
37. Van Meir EG, Bellail A, Phuphanich S. Emerging molecular therapies for brain tumors. Semin Oncol 2004; 31 (2 Suppl.):38-46.
38. Bello L, Giussani C, Carrabba G, et al. Angiogenesis and invasion in gliomas. Cancer Treat Res 2004; 117:263-284.
39. Ziehe M, Donnini S, Morbidelli L. Development of new drugs in angiogenesis. Curr Drug Targets 2004; 5:485-493. A recent review of anti-angiogenic drugs under evaluation.
40. Bogler O, Mikkelsen T. Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J 2003; 9:205-213. A recent review of anti-angiogenic therapy for gliomas.
41. Goldbrunner RH, Bendszus M, Wood J, et al. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004; 55:426-432.
42. Readon D, Friedman H, Yung WKA, et al. A phase I trial of PTK787/ZK 222584 (PTK/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). In: Proceedings of the American Society of Clinical Oncology. New Orleans, 4-8 June 2004 [Abstract 1513].
43. Sandstrom M, Johansson M, Andersson U. The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 2004; (Epub ahead of print).
44. Ruggeri B, Singh J, Gingrich D, et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 2003; 63:5978-5991.
45. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64:4931-4941.
46. Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol 2004; 15:1151-1160.
47. Morabito A, Fanelli M, Carillio G, et al. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol Rep 2004; 11:93-95.
48. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708-715.
49. Marx GM, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2001; 54:31-38.
50. Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003; 21:2299-2304.
51. Baumann F, Bjeljac M, Kollias SS, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004; 67:191-200.
52. Groves MD, Tremont-Lukats IW, Conrad C, et al. A phase II trial of temozolomide plus thalidomide (NABTC 99-04) for recurrent malignant glioma. Proceedings of the 5th Congress of the European Association for Neuro-Oncology. Neuro-Oncology 2002; 4:341.
53. Yoshida D, Takahashi H, Teramoto A. Inhibition of glioma angiogenesis and invasion by SI-27, an anti-matrix metalloproteinase agent in a rat brain tumor model. Neurosurgery 2004; 54:1213-1220.
54. Fine HA, Kim L, Royce C, et al. A phase II trial of LY317615 in patients with recurrent high grade gliomas. In: Proceedings of the American Society of Clinical Oncology. New Orleans, 4-8 June 2004 [Abstract 1511].
55. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenaase-2 inhibitors. Cancer Res 2000; 60:1306-1311.
56. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2000; 60:4926-4931.
57. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001; 61:4375-4381.
58. Giglio P, Levin V. Cyclooxygenase-2 inhibitors in glioma therapy. Am J Ther 2004; 11:141-143.
59. Badie B, Schartner JM, Hagar AR, et al. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin Cancer Res 2003; 9:872-877.
60. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3:745-755.
61. Sanchez C, de Ceballos ML, del Pulgar TG, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001; 61:5784-5789.
62. Blazquez C, Gonzalez-Feria L, Alvarez L, et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004; 64:5617-5623.
63. Abdollahi A, Lipson KE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003; 63:8890-8898.
64. Zalutsky MR. Targeted radiotherapy of brain tumors. Br J Cancer 2004; 90:1469-1473. A recent review of targeted radiotherapy for brain tumors.
65. Reardon DA, Akabani G, Coleman R, et al. Phase II trial of murine 131 I-labelled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 20:1389-1397.
66. Goetz C, Riva P, Poepperl G, et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 2003; 62:321-328.
67. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 1251-labelled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 2004; 58:972-975.
68. Bigner D, Brown M, Friedman AH, et al. Iodine-131-labelled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998; 16:2202-2212.
69. Bobo, RH, Laske, DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994; 91:2076-2080.
70. Morrison PF, Laske DW, Bobo H, et al. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 1994; 266:R292-R305.
71. Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 1994; 58:574-581.
72. Kawakami M, Kawakami K, Puri RK. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 2003; 65:15-25.
73. Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003; 88:93-103.
74. Rainov NG, Heidecke V. Long term survival in a patient with recurrent malignant glioma treated with intratumora/ infusion of an IL4-targeted toxin (NBI-3001). J Neurooncol 2004; 66:197-201.
75. Kunwar S, Prados M, Chang S, et al. Peritumoral convection-enhanced delivery of IL-13-PE38QQR in patients with recurrent malignant glioma-phase I interim results. Neuro-Oncology 2003; 5:350 [Abstract TA-15].
76. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003; 88:105-111.
77. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65:27-35.
78. Cohen KA, Liu T, Bissonette R, et al. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr Pharm Biotechnol 2003; 4:39-49.
79. Mamelak AN, Raubitschek A, Morgan R, et al. A phase I/II trail of intracavitary 131I-TM-601 in adult patients with recurrent high-grade-glioma. Neuro-Oncology 2003; 6:340 [Abstract RA-19].
80. Rustamzadeh E, Li C, Doumbia S, Hall WA, Vallera DA. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol 2003; 65:63-75.
81. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 2004; 3:737-745.
82. Bogdahn U, Hau P, Brawanski A, et al. Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009. In: Proceedings of the American Society of Clinical Oncology. New Orleans, 4-8 June 2004 [Abstract 1514].
83. Li KW, Dang W, Tyler BM, Troiano G, et al. Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin Cancer Res 2003; 9:3441-3447.
84. Menei P, Benoit JP. Implantable drug-releasing biodegradable microspheres for local treatment of brain glioma. Acta Neurochir Suppl 2003; 88:51-55.
85. Menei P, Jadaud E, Faisant N, et al. Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer 2004; 100:405-410.
86. Basso U, Ermani M, Vastola F, Brandes AA. Non-cytotoxic therapies for malignant gliomas. J Neurooncol 2002; 58:57-68.
87. Jendrossek V; Belka C; Bamberg M. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Exp Opin Invest Drugs 2003; 12:1899-1924.
88. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004; 3;430-446. A recent review of targeted molecular therapies for malignant gliomas.
89. Couldwell WT, Weiss MH, DeGiorgio CM, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993; 32:485-489.
90. Chamberlain MC, Kormanik PA. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 1999; 56:703-708.
91. Hercbergs AA, Goyal LK, Suh JH, et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 2003; 23:617-626.
92. See S-J, Levin VA, Yung WKA, et al. 13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro-Oncology 2004; 6:253-258.
93. Wismeth C, Hau P, Fabel K, et al. Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy - a phase-II study. J Neurooncol 2004; 68:79-86.
94. Puduvalli VK, Yung WKA, Hess KR, et al. A phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: a North American Brain Tumor Consortium (NABTC) Study. J Clin Oncol 2004; in press.
95. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, et al. The effect of taurolidine on brain tumor cells. Anticancer Res 2002; 22:809-814.
96. Stendel R, Picht T, Schilling A. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 2004; 24:1143-1147.
97. Grossman SA, Phuphanich S, Lesser G, et al. New Approaches to Brain Tumor Therapy CNS Consortium. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J Clin Oncol 2001; 19:3260-3266.
98. Laterra JJ, Grossman SA, Carson KA, et al., NABTT CNS Consortium study. Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro-oncol 2004; 6:15-20.
99. Robe PA, Bentires-Alj M, Bonif M, et al. In vitro and in vivo activity of the nuclear factor-{kappa}B inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 2004; 10:5595-5603.